






The Open Access Institutional Repository 




This is an author produced version of a paper published in  
 
Oncology Letters (ISSN 1792-1074, eISSN 1792-1082) 
 
This version may not include final proof corrections and does not include 





Citation for the version of the work held in ‘OpenAIR@RGU’: 
 
WEICHHAUS, M., BROOM, J., WAHLE, K. and BERMANO, G., 2014. 
Leptin inhibits proliferation of breast cancer cells at 
supraphysiological concentrations by inhibiting mitogen-activated 
protein kinase signaling. Available from OpenAIR@RGU. [online]. 
Available from: http://openair.rgu.ac.uk 
 
 
Citation for the publisher’s version: 
 
WEICHHAUS, M., BROOM, J., WAHLE, K. and BERMANO, G., 2014. 
Leptin inhibits proliferation of breast cancer cells at 
supraphysiological concentrations by inhibiting mitogen-activated 





Items in ‘OpenAIR@RGU’, Robert Gordon University Open Access Institutional Repository, 
are protected by copyright and intellectual property law. If you believe that any material 
held in ‘OpenAIR@RGU’ infringes copyright, please contact openair-help@rgu.ac.uk with 
details. The item will be removed from the repository while the claim is investigated. 
ONCOLOGY LETTERS  8:  374-378,  2014374
Abstract. Leptin is a hormone secreted by white fat tissue and 
signals the amount of overall body fat to the hypothalamus. The 
circulating concentration of leptin correlates with the level of 
obesity. Breast cancer risk is higher in obese postmenopausal 
women compared with postmenopausal women of a normal 
weight, and high leptin concentrations may contribute to this 
risk. In the present study, SK-BR-3 and MDA-MB-231 breast 
cancer cell lines were treated with various concentrations 
(6.25-1,600 ng̸ml) of recombinant leptin and changes in cell 
proliferation were assessed. The SK-BR-3 breast cancer cells 
exhibited a concentration-dependent increase in proliferation 
with physiological leptin concentrations (<100 ng̸ml), but no 
further increase in proliferation at high leptin concentrations 
(>100 ng̸ml) was observed. Cell proliferation was not affected 
at supraphysiological leptin concentrations (>800 ng̸ml) in 
SK-BR-3 cells, whereas it decreased in MDA-MB-231 cells. 
Therefore, cell signaling and cell cycle changes were assessed 
at supraphysiological concentrations (1,600 ng̸ml). In the two 
cell lines, leptin treatment decreased the mitogen-activated 
protein kinase (MAPK) cell signaling pathway activation. 
Leptin treatment did not increase Akt phosphorylation or 
significantly alter the cell population distribution across cell 
cycle stages. To the best of our knowledge, leptin-induced 
growth inhibition of breast cancer cells at supraphysiological 
concentrations has not been reported in the literature to date, 
and the findings of this study suggest that reduced MAPK 
activity may be the underlying cause. Thus, the effect of leptin 
on breast cancer growth warrants further investigation since 
leptin is considered to be one of the main mediators in the 
obesity-breast cancer connection.
Introduction
Obesity, the accumulation of excess fat tissue, is a risk factor 
for the development of postmenopausal breast cancer (1). The 
molecular changes in metabolism associated with obesity are 
thought to contribute to this phenomenon (2). One of these 
molecular changes is increased circulating leptin levels in 
obese individuals (3). Leptin is a 16 kDa peptide hormone 
predominantly produced by white fat tissue (4). Its main 
function is to signal to the hypothalamus, which in response 
regulates satiety and energy expenditure (5). Notably, leptin 
is also responsible for the normal formation of the mammary 
gland in humans (6), suggesting an involvement in mammary 
tissue growth and differentiation, and potentially malignant 
transformation. Epidemiologically, leptin concentrations are 
higher in patients with breast cancer compared with healthy 
individuals, independent of body weight (7). Additionally, 
leptin receptor (Ob-R) expression is increased in breast tumor 
tissue compared with surrounding tissue (8). Breast cancer cell 
lines have also been found to express leptin and Ob-R (9).
Previous in vitro experiments investigating the effects of 
leptin treatment on cell proliferation and tumor growth have 
revealed conflicting results. In MDA‑MB‑231 breast cancer 
cells, leptin induced a robust concentration-dependent increase 
in proliferation in two independent studies (10,11). Conversely, 
in MCF-7 breast cancer cells, leptin treatment increased (12) 
and decreased (11) proliferation. Similarly, in human epidermal 
growth factor (HER)-2 overexpressing SK-BR-3 breast cancer 
cells, leptin treatment increased proliferation between 5 and 
50 ng̸ml, but not at 100 ng̸ml (11). These controversial find-
ings warrant the need for further investigation into the effects 
of leptin on proliferation in a human breast cancer in vitro cell 
system. 
Notably, a number of studies investigating the effect of 
cytokines on proliferation changes in cell culture models 
used concentrations which are several-fold greater than the 
highest known physiological concentration, such as insulin 
treatment (13,14) or tumor necrosis factor-α treatment (15,16). 
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However, previous studies investigating the effect of leptin 
treatment on proliferation in breast cancer cells (10,11,17) did 
not or only marginally exceeded maximal physiological leptin 
concentrations of 100 ng̸ml (3). The highest leptin concentra-
tion used in vitro to examine changes in T47D breast cancer cell 
proliferation was 1,000 ng̸ml. However, increased cell prolif-
eration was only observed with up to 100 ng̸ml leptin (18). 
Thus, while previous data appear to indicate a growth inhibi-
tory effect of leptin at above physiological concentrations, 
it has not yet been fully investigated. Therefore, the present 
study aimed to explore the effects of supraphysiological leptin 
concentrations on proliferation in two breast cancer cell lines. 
The present study aimed to investigate the effects of physi-
ological and supraphysiological levels of leptin (≤1,600 ng̸ml) 
on proliferation in SK-BR-3 and MDA-MB-231 breast cancer 
cells, two cell lines representative of HER-2-positive and 
basal-type breast cancer subtypes, respectively. The activation 
of phosphatidylinositide 3-kinase (PI3K) and mitogen-acti-
vated protein kinase (MAPK) cell signaling pathways and 
distribution across cell cycle stages were assessed in the two 
cell lines following treatment with 1,600 ng̸ml leptin.
Materials and methods
Cell lines. SK-BR-3 and MDA-MB-231 breast cancer cell lines 
were purchased from the American Type Culture Collection 
(Manassas, VA, USA). The two cell lines were routinely 
cultured in RPMI-1640 medium (including 25 mM HEPES, 
1X Glutamax™; Gibco, Paisley, UK) supplemented with 10% 
fetal calf serum (FCS; Pierce Biosciences, Cramlington, UK), 
100 U̸ml penicillin and 100 µg̸ml streptomycin (Gibco). 
Bromodeoxyuridine (BrdU) proliferation assay. Cell prolif-
eration was detected using the Proliferation ELISA kit (Roche 
Diagnostics GmbH, Penzberg, Germany). The two cell lines 
were plated at a density of 5x103 cells̸well in 96-well plates 
with 100 µl̸well growth medium and incubated for 24 h at 
37˚C. Cells were starved for 24 h in RPMI-1640 medium 
without FCS supplementation, and then treated for 24 or 48 h 
with 6.25-1,600 ng̸ml leptin in replicates of six in starvation 
medium. During treatment, the medium was supplemented 
with 10 µM BrdU. Cell proliferation was assessed as previ-
ously described (16). The experiment was repeated for a total 
of three independent times. Each experiment had six replicates 
for each leptin concentration.
PI3K and MAPK phosphorylation ELISA. Cell-based ELISA 
Phospho-Akt (S473) Immunoassay and Phospho-extracellular 
signal-regulated kinase (ERK)1̸ERK2 (T202̸Y204) 
Immunoassay were purchased from R&D Systems (Abingdon, 
UK). The cells were plated in a supplied clear bottom, 
black-walled, 96-well plate at a density of 5x103 cells̸well 
with 100 µl̸well growth medium, and incubated for 24 h at 
37˚C. The cells were starved for 24 h as mentioned above 
and then treated with 1,600 ng̸ml leptin for 5-20 min in 
duplicates. Phosphorylation of protein kinase B (Akt) or 
ERK1̸2 was then assessed as previously described (16). The 
experiment was repeated for a total of three independent 
experiments with two replicates for each time point in each 
experiment.
Cell cycle analysis. Changes in the cell distribution across 
cell cycle stages were assessed by measuring the DNA content 
in cells using flow cytometry following leptin treatment. The 
DNA-specific dye was propidium iodide (PI; Sigma‑Aldrich, 
Gillingham, UK). The cells were plated at a density of 
5x105 cells̸well in six-well plates with 3 ml growth medium, 
and incubated for 24 h at 37˚C. The cells were starved for 24 h, 
treated with 1,600 ng̸ml leptin for 24 h and then harvested, 
treated and analyzed as described previously (16).
Statistical analysis. The findings were analyzed for statistical 
significance using univariate analysis of variance between the 
control and each treatment concentration for cell proliferation 
analysis and between the control and each time point in the 
cell signaling pathway analysis, followed by Dunnett's post hoc 
t-tests. Differences in the distribution across cell cycle stages 
between the control and leptin-treated cells were assessed for 
each cell cycle stage using Student's t-test. P<0.05 was consid-
ered to indicate a statistically significant difference.
Results
Changes in cell proliferation following leptin treatment. In 
the SK-BR-3 cells, proliferation increased by 61, 96, 104, 115, 
115, 110 and 51% following treatment with 6.25, 12.5, 25, 50, 
100, 200 and 400 ng̸ml leptin, respectively, for 24 h compared 
with the untreated control (all P<0.001) (Fig. 1A). There was 
no significant difference in cell proliferation between the 
untreated cells and cells treated with 800 or 1,600 ng̸ml leptin 
for 24 h (Fig. 1A). After 48 h of treatment, cell proliferation 
increased significantly by 44, 53, 53, 69, 75, 69, 52 and 33% 
following treatment with 6.25, 12.5, 25, 50, 100, 200, 400 ng̸ml 
(all P<0.001) and 800 ng̸ml (P=0.009) leptin, respectively 
compared with the untreated control (Fig. 1B). There was 
no change in proliferation after 48 h of treatment with 
1,600 ng̸ml leptin (Fig. 1B). In MDA-MB-231 breast cancer 
cells, proliferation did not change significantly after 24 h of 
treatment with leptin (Fig. 1C) and decreased significantly by 
11% (P=0.023) and 26% (P<0.001) after 48 h of treatment with 
400 and 800 ng̸ml (P<0.001) of leptin, respectively, compared 
with the untreated control (Fig. 1D). Based on the findings 
obtained on growth inhibition following treatment with 
1,600 ng̸ml leptin, cell signaling and cell cycle changes were 
assessed to determine the underlying mechanisms responsible 
for growth inhibition in the two breast cancer cell lines.
Changes in PI3K and MAPK cell signaling pathway 
activity following leptin treatment. In the SK-BR-3 cells, 
Akt‑phosphorylation did not change significantly following 
treatment with 1,600 ng̸ml leptin for up to 20 min compared 
with the control (Fig. 2A). ERK1̸2-phosphorylation decreased 
by 32 and 34% after 10 (P<0.001) and 15 min (P<0.001) of 
treatment with 1,600 ng̸ml leptin, respectively, compared 
with the control (Fig. 2B). In the MDA-MB-231 cells, 
Akt‑phosphorylation did not change significantly following 
treatment with 1,600 ng̸ml leptin (Fig. 2C), whereas 
ERK1̸2‑phosphorylation decreased significantly by 17 and 
20% after 15 (P=0.026) and 20 min (P=0.011) of treatment 
with 1,600 ng̸ml leptin, respectively, compared with the 
control (Fig. 2D).
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Figure 2. Changes in (A and C) Akt phosphorylation and (B and D) ERK1/2 phosphorylation as indicators of changes in the PI3K or MAPK cell signaling 
pathway, respectively, following 1,600 ng/ml leptin treatment of (A and B) SK-BR-3 and (C and D) MDA-MB-231 breast cancer cells for the indicated time 
periods. Bars represent Akt or ERK1/2-phosphorylation in relation to their respective control within each graph, and are expressed as a percentage of the 
control. Error bars represent standard error of the mean of three experiments, each consisting of two replicates, i.e., six data points for each bar. Significance 
was obtained using Dunnett's post hoc t-test following univariate analysis of variance (*P<0.05, vs. the control). ERK, extracellular signal-regulated kinase; 
PI3K, phosphatidylinositide-3 kinase; MAPK, mitogen-activated protein kinase.
Figure 1. Changes in cell proliferation following treatment of (A and B) SK-BR-3 and (C and D) MDA-MB-231 breast cancer cells for (A and C) 24 h and (B 
and D) 48 h, with a range of leptin concentrations. Bars represent BrdU incorporation in relation to the respective control within each graph, and are expressed 
as a percentage of the control. Error bars represent standard error of the mean of two experiments, each consisting of six replicates, i.e., 12 data points for 
each bar. Significance was determined using Dunnett's post hoc t-test following one-way analysis of variance (*P<0.05, **0.01<P<0.001 and ***P<0.001, vs. the 
control). BrdU, bromodeoxyuridine
  A   B
  C   D
  A   B
  C   D
Table I. Changes of cell population distribution across cell cycle stages after 24 h of treatment with 1,600 ng/ml leptin.
 SK-BR-3 cells MDA-MB-231 cells
 ---------------------------------------------------------------- ---------------------------------------------------------------
Cell cycle stage (%) Control Leptin-treated P-value Control Leptin-treated P-value
SubG1 20.56±3.01 20.4±1.68 0.2189 17.00±1.07 18.15±1.33 0.5077
G0/G1 39.90±2.00 44.385±2.10 0.1490 55.12±0.97 54.14±0.99 0.3830
S 6.30±0.45 5.86±0.81 0.6444 7.23±0.65 6.96±0.62 0.7677
G2 15.98±0.70 14.03±0.87 0.0863 12.88±0.43 12.71±0.48 0.4257
Values represent the mean ± standard error of three independent experiments. P-values were determined by Student's t-test. Each experiment 
had two replicates, i.e., six data points for control and treatment.
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Changes in distribution of cell population across cell cycle 
stages. In the SK-BR-3 cells, 1,600 ng̸ml leptin treatment may 
increase the G1-phase population and decrease the G2-phase 
population (Table I). Cells in the G1-phase increased by 4.5 
percentage points (11% increase) and cells in the G2-phase 
decreased by 2.0 percentage points (12% decrease). In 
MDA-MB-231 cells, the subG1-phase population increased 
by 1.2 percentage points (7% increase) and the G1-phase 
population decreased by 1.0 percentage point (2% decrease) 
following treatment with 1,600 ng̸ml leptin (Table I). None of 
the observed changes were significantly different.
Discussion
Previous in vitro studies have demonstrated that leptin induces 
cell proliferation in a variety of breast cancer cell types, within 
physiological concentrations (25‑100 ng̸ml) (6,9‑12,18). 
Conversely, the same studies did not observe increased 
cell proliferation with leptin concentrations exceeding 
100 ng̸ml. The findings of the present study confirmed the 
increased cell proliferation in SK-BR-3 breast cancer cells, 
but not in MDA-MB-231 cells at physiological concentrations. 
Furthermore, leptin treatment at supraphysiological concentra-
tions did not increase cell proliferation in the SK-BR-3 cells, 
but inhibited proliferation of the MDA-MB-231 cells. To the 
best of our knowledge, this study was the first to indicate 
the potential of leptin treatment to inhibit cell proliferation 
in breast cancer cells. The mechanism by which supraphysi-
ological leptin concentrations induce growth inhibition may 
involve decreased activation of the Ras-mediated MAPK 
pathway. 
As a potential explanation, leptin may interact with the 
HER-2̸neu receptor in SK-BR-3 breast cancer cells, which is 
overexpressed in these cells, resulting in decreased MAPK 
activity. Soma et al reported that SK-BR-3 cells treated with 
leptin (500 ng̸ml) resulted in increased phosphorylation of the 
HER‑2̸neu receptor (20). This cross‑talk was identified as being 
responsible for an increase in ERK1̸2 phosphorylation, which 
was also observed following leptin treatment. The findings of 
the present study suggest that at higher leptin concentrations, 
this effect is inhibited. This may either be by high leptin levels 
inhibiting the potential of HER‑2/neu to activate ERK1̸2 or 
by inhibiting ERK1̸2 phosphorylation directly. HER‑2̸neu 
and Ob-R transduct their proliferative signal through the 
PI3K and̸or MAPK pathways (21), suggesting there may be 
an interaction on the targets downstream of the two receptors. 
Thus, leptin may have at least two modes of action, which 
appear to be antagonistic. First, leptin increases phosphoryla-
tion of HER-2̸neu, which results in increased proliferation of 
SK‑BR‑3 breast cancer cells; second, leptin inhibits ERK1̸2 
phosphorylation, which is predominant at high leptin concen-
trations, thereby reducing the effect of increased HER‑2̸neu 
signaling. 
In MDA-MB-231 breast cancer cells, which are 
HER‑2‑negative, interplay with HER‑2̸neu cannot account 
for the observed reduction in proliferation, indicating that 
growth inhibition at supraphysiological leptin concentrations 
is HER-2/neu independent. In a study aiming to potentiate the 
antitumor effects of cAMP-agonists, leptin induced apoptosis 
in MDA-MB-231 breast cancer cells when cAMP levels were 
increased (22), which resulted in ERK1̸2 inactivation and 
the subsequent inhibition of protein kinase A (PKA) expres-
sion (23). Thus, at supraphysiological concentrations, leptin 
may not require elevated cAMP levels to decrease PKA, and 
this may provide a mechanism for the effects observed in our 
study.
These findings suggest that leptin exerts a biphasic effect 
on cell proliferation in SK-BR-3 breast cancer cells and that 
leptin signaling may play a role in breast cancer development 
and progression. Therefore, the inhibition of leptin signaling 
may be relevant for breast cancer prevention, particularly for 
obese individuals showing high levels of leptin and occurrence 
of breast cancer. Nutritional interventions (24) or anti-leptin 
treatment (25) may be considered as a potential preventative 
strategy and treatment for HER‑2̸neu overexpressing breast 
tumors, respectively. Further investigations into the inhibi-
tory effects of leptin at high concentrations may reveal the 
unknown mechanisms in the connection between obesity and 
postmenopausal breast cancer.
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